araag2/HINT huggingface dataset:
Clinical trial NCT01966822 (phase 3, status: completed)
Conditions: hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: dolutegravir, 50mg every 24 hours, protease inhibitor/ritonavir
SMILES: [H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2
Eligibility criteria:

        Inclusion Criteria:

          1. HIV-infected patients over 18 years.

          2. In current antiretroviral therapy with abacavir and lamivudine (Kivexa) plus
             ritonavir-boosted PI, at least 6 months.

          3. Viral suppression (HIV RNA <50 copies / ml) for at least 12 months.

          4. T-score ≤ -1 evaluated by DEXA (done in the last 6 months).

          5. Signed informed consent.

          6. In potential childbearing women, commitment to use barrier contraceptive method
             throughout the study.

        Exclusion Criteria:

          1. Suspected or documented resistance to integrase inhibitors or reverse transcriptase
             inhibitors, nucleoside analogues.

          2. Osteoporosis / osteopenia secondary (testosterone deficiency, thyroid disease ...),
             except vitamin D deficiency

          3. Treatment with bisphosphonates in the last 6 months.

          4. Have used integrase inhibitors

          5. Pregnant or breastfeeding.

          6. Patients with alanine aminotransferase (ALT)> 5 times the upper limit of normal (ULN)
             or ALT ≥ 3 times ULN and bilirubin ≥ 1.5 times ULN (direct bilirubin> 35%)

          7. Patients with severe hepatic dysfunction (Class B or C) according to the Child-Pugh
             classification

          8. Patients infected with hepatitis B virus (HBV) who can not use entecavir or
             telbivudine.

          9. Patients infected with hepatitis C virus (HCV) in which is expected to begin treatment
             during the study.
Clinical trial NCT01968213 (phase 3, status: active, not recruiting)
Conditions: ovarian cancer, fallopian tube cancer, peritoneal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: rucaparib, placebo
SMILES: CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian, primary
             peritoneal, or fallopian tube cancer.

          -  Received ≥2 prior platinum-based treatment regimens including platinum based regimen
             that must have been administered immediately prior to maintenance therapy in this
             trial.

          -  Received no more than 1 non-platinum chemotherapy regimen. Prior hormonal therapy will
             not be counted as a non-platinum regimen.

          -  Must have had at least a 6-month disease-free period following prior treatment with
             the penultimate platinum-based chemotherapy and achieved a response.

          -  For the last chemotherapy course prior to study entry, patients must have received a
             platinum-based doublet chemotherapy regimen and have achieved a CR or PR (as defined
             by RECIST) and/or a GCIG CA-125 response.

          -  Have sufficient archival tumor tissue for analysis.

        Exclusion Criteria:

          -  History of prior cancer except for non-melanoma skin cancer, breast cancer curatively
             > 3 years ago, curatively treated solid tumor (>5 years ago without evidence of
             recurrence), and synchronous endometrial cancer (Stage 1A) with ovarian cancer.

          -  Prior treatment with any PARP inhibitor, including rucaparib. Patients who received
             prior iniparib are eligible.

          -  Untreated or symptomatic central nervous system metastases.

          -  Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would,
             in the opinion of the Investigator, interfere with absorption of study drug.

          -  Required drainage of ascites during the final 2 cycles of their last platinum-based
             regimen and/or during the period between the last dose of chemotherapy of that regimen
             and randomization to maintenance treatment in this study.
Clinical trial NCT01973790 (phase 3, status: completed)
Conditions: dyspepsia
ICD codes: K30
Drugs: z-338
SMILES: COC1=C(OC)C=C(C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C)C(O)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects to provide written informed consent prior to any study procedures being
             performed

          -  Subjects with a diagnosis of FD (postprandial distress syndrome) as defined by the
             Rome III Criteria

          -  Subjects must present Postprandial Fullness or Early Satiation as the most bothersome
             symptom during the 6 months prior to informed consent.

          -  Subjects must have a normal endoscopy result within the 6 months (3 months in case of
             subjects who are Helicobacter pylori positive) prior to informed consent or during the
             screening period.

        Exclusion Criteria:

          -  Subjects on PPI(s) who are unable to discontinue PPI medication by the end of the
             screening period

          -  Subjects taking drugs that affect gut motility, gut sensitivity and/or acid secretion
             who are unable to discontinue these drugs by the end of the screening period

          -  Subjects who have received H. pylori eradication therapy during the 3 months prior to
             informed consent

          -  Subjects with confirmed organic gastrointestinal disease

          -  Subjects presenting with predominant complaints relieved by stool movements (irritable
             bowel syndrome)

          -  Subjects presenting with predominant GORD symptoms

          -  Subjects presenting with predominant complaints of chronic idiopathic nausea

          -  Subjects with Type I or Type II diabetes

          -  Subjects with body mass index (BMI) over 30 kg/m2

          -  Subjects with any condition which, in the opinion of the Investigator, makes the
             subject unsuitable for entry into the study
Clinical trial NCT01980875 (phase 3, status: terminated)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: idelalisib, chlorambucil, obinutuzumab
SMILES: [H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1, OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl
Eligibility criteria:

        Key Inclusion Criteria:

          -  Not a candidate for fludarabine therapy based on either:

               1. creatinine clearance < 70 mL/min, or

               2. Cumulative Illness Rating Scale score > 6, by assessment of the investigator

          -  Diagnosis of B-cell CLL, with diagnosis established according to International
             Workshop on Chronic Lymphocytic Leukemia (IWCLL)

          -  No prior therapy for CLL other than corticosteroids for disease complications.

          -  CLL that warrants treatment

          -  Presence of measurable lymphadenopathy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

        Key Exclusion Criteria:

          -  Known histological transformation from CLL to an aggressive lymphoma (ie, Richter
             transformation)

          -  Known presence of myelodysplastic syndrome

          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
             randomization

          -  Ongoing liver injury

          -  Ongoing drug-induced pneumonitis

          -  Ongoing inflammatory bowel disease

          -  History of prior allogeneic bone marrow progenitor cell or solid organ transplantation

          -  Ongoing immunosuppressive therapy other than corticosteroids

          -  Concurrent participation in another therapeutic clinical trial

          -  Undergone major surgery within 30 days prior to randomization

          -  Known hypersensitivity or intolerance to any of the active substances or excipients in
             the formulations for idelalisib, obinutuzumab, or chlorambucil

          -  History of non-infectious pneumonitis

          -  Received last dose of study drug on another therapeutic clinical trial within 30 days
             prior to randomization

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT01980888 (phase 3, status: terminated)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: idelalisib, bendamustine, rituximab, placebo
SMILES: [H][C@@](CC)(NC1=NC=NC2=C1N=CN2)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Documented diagnosis of B-cell CLL, with diagnosis established according to
             International Workshop on Chronic Lymphocytic Leukemia (IWCLL)

          -  No prior therapy for CLL other than corticosteroids for disease complications

          -  CLL that warrants treatment

          -  Presence of measurable lymphadenopathy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

        Key Exclusion Criteria:

          -  Known histological transformation from CLL to an aggressive lymphoma (ie, Richter
             transformation)

          -  Known presence of myelodysplastic syndrome

          -  Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
             randomization

          -  Ongoing liver injury

          -  History of non-infectious pneumonitis

          -  Ongoing inflammatory bowel disease

          -  History of prior allogeneic bone marrow progenitor cell or solid organ transplantation

          -  Ongoing immunosuppressive therapy other than corticosteroids

          -  Received last dose of study drug on another therapeutic clinical trial within 30 days
             prior to randomization

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT01986101 (phase 3, status: completed)
Conditions: bipolar depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: placebo, sm-13496, sm-13496
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O, [H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=CC=CC=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who were fully informed of and understand the objectives, procedures, and
             possible benefits and risks of the study and who provided written voluntary consent to
             participate in the study.

          -  Outpatients aged 18 through 74 years at the time of consent

          -  Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode
             depressed (≥ 4 weeks and less than 12 months) without psychotic features.

        Exclusion Criteria:

          -  Patients with imminent risk of suicide or injury to self, others, or property.

          -  Patients who had been hospitalized because of a manic or mixed episode within 60 days
             prior to screening.

          -  Patients who are otherwise considered ineligible for the study by the investigator.
Clinical trial NCT01986127 (phase 3, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: adalimumab, placebo
SMILES: O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    slow recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients of both sexes older than 18 years

          -  Patient diagnosed of CROHN´s disease

          -  Patient with intestinal stenosis length equal or less than 5cm previously confirmed
             with bowel magnetic resonance imaging (3 stenosis as maximum)

          -  Stenosis no permeable for endoscopy(12mm in case of accessible stenosis with
             conventional colonoscopy and 10mm in case of accessible stenosis with balloon
             enteroscopy)

          -  Dilated stenosis according to endoscopist criteria (pass or no the endoscopy)

          -  Patient capable of participate in the examinations required by the study

          -  Patient after being informed, give his/her informed consent in writing

        Exclusion Criteria:

          -  Patients with large intestinal stenosis (more than 6cm) and multiples

          -  Patients with previous or actual treatment with anti-tumor necrosis factor (anti-TNF)
             drugs

          -  Patients with positive serology to hepatitis B virus(HBV),hepatitis C virus (HCV), or
             HIV

          -  Patients with positive screening to Tuberculosis(positive PPD)

          -  Established contraindication to anti-TNF drugs

          -  Existence of fistulous tracts associated with intestinal stenosis

          -  Neoplastic process associated with stenosis or in another location

          -  Pregnancy or breastfeeding
Clinical trial NCT01987895 (phase 3, status: completed)
Conditions: clostridium difficile infection
ICD codes: A05.2, A04.71, A04.72, B96.7
Drugs: cadazolid, vancomycin, cadazolid-matching placebo, vancomycin-matching placebo
SMILES: OC[C@H]1CN(C(=O)O1)C1=CC(F)=C(OCC2(O)CCN(CC2)C2=C(F)C=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O)C=C1, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed Informed Consent.

          -  Male or female ≥ 18 years of age. Females of childbearing potential must agree to use
             an adequate and reliable method of contraception.

          -  Subject with a diagnosis of mild-moderate or severe CDAD (first occurrence or first
             recurrence within 3 months) with: Diarrhea: a change in bowel habits with > 3 liquid
             or unformed bowel movements (UBM) within 24 hours prior to randomization, AND Positive
             C. difficile toxin test on a stool sample produced within 72 hours prior to
             randomization.

        Exclusion Criteria:

          -  More than one previous episode of CDAD in the 3-month period prior to randomization.

          -  Evidence of life-threatening or fulminant CDAD.

          -  Likelihood of death within 72 hours from any cause.

          -  History of inflammatory colitides, chronic abdominal pain, or chronic diarrhea.

          -  Antimicrobial treatment active against CDAD administered for > 24 hours except for
             metronidazole treatment failures (MTF)

          -  Known hypersensitivity or contraindication to study drugs, oxazolidinones, or
             quinolones.

          -  Unable or unwilling to comply with all protocol requirements.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol
Clinical trial NCT01989676 (phase 3, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: paclitaxel, paclitaxel
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of breast cancer.

          -  Presence of metastatic disease.

          -  Documentation of HER2 gene amplification or overexpression.

          -  Available tumor tissue for central review of HER2 status.

          -  At least 1 measurable lesion as defined by RECIST 1.1.

          -  Eastern Cooperative Oncology Group status of 0 to 2.

          -  Left ventricular ejection fraction within institutional range of normal, measured by
             either two dimensional echocardiogram or multigated acquisition scan.

        Exclusion Criteria:

          -  Relapse within 1 year of last dose of previous adjuvant (including neoadjuvant)
             treatment (except endocrine therapy) and within 1 year before randomization.

          -  Prior systemic therapy for metastatic disease (except endocrine therapy).

          -  Prior cumulative dose of doxorubicin of >400 mg/m2, epirubicin dose >800 mg/m^2, or
             the equivalent dose for other anthracyclines or derivatives (eg, 72 mg/m^2 of
             mitoxantrone). If the patient has received more than one anthracycline, then the
             cumulative dose must not exceed the equivalent of 400 mg/m^2 of doxorubicin.

          -  Inflammatory breast cancer.

          -  Active uncontrolled or symptomatic central nervous system metastases.
Clinical trial NCT01991795 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ticagrelor 60 mg, ticagrelor placebo
SMILES: CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

        Men or women ≥50 years of age with type 2 diabetes mellitus on treatment with a glucose
        lowering medication since at least 6 months, and either documented coronary artery
        occlusive disease or previous revascularization of a coronary artery.

        Key Exclusion Criteria:

        History of myocardial infarction or any stroke; planned treatment with agents inhibiting
        blood clotting; planned use of ASA/Aspirin at doses above 150 mg daily; planned coronary,
        cerebrovascular, or peripheral arterial revascularization; patients with known bleeding
        disorders and patients who need chronic oral anticoagulant therapy or chronic
        low-molecular-weight heparin; history of intracranial bleeding at any time, or a history of
        bleeding from the gastrointestinal tract within the last 6 months or a major surgery within
        the last 30 days; patients with known severe liver disease or with kidney failure requiring
        dialysis
Clinical trial NCT01994720 (phase 3, status: completed)
Conditions: acute ischaemic stroke, transient ischaemic attack
ICD codes: R29.5, F95.0, G45.4, P61.0, P61.5, D80.7, H53.123
Drugs: ticagrelor, acetylsalicylic acid (asa)
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women equal or elder 40 years of age

          -  Either acute ischaemic stroke or high-risk TIA as defined here and randomisation
             occurring within 24 hours after onset of symptoms

        Key Exclusion Criteria:

          -  Planned use of antithrombotic therapy in addition to study medication including
             antiplatelets (eg, open label ASA, GPIIb/IIIa inhibitors, clopidogrel, ticlopidine,
             prasugrel, dipyridamole, ozagrel, cilostazol) and anticoagulants (eg, warfarin, oral
             thrombin and factor Xa inhibitors, bivalirudin, hirudin, argatroban, unfractionated
             and low molecular weight heparins). - Any history of atrial fibrillation, ventricular
             aneurysm or suspicion of cardioembolic pathology for TIA or stroke. - Planned carotid,
             cerebrovascular, or coronary revascularisation that requires halting study medication
             within 7 days of randomisation. - Receipt of any intravenous or intra-arterial
             thrombolysis or mechanical thrombectomy within 24 hours prior to randomisation -
             History of previous symptomatic non-traumatic intracerebral bleed at any time
             (asymptomatic microbleeds do not qualify), gastrointestinal (GI) bleed within the past
             6 months, or major surgery within 30 days.
Clinical trial NCT02000622 (phase 3, status: active, not recruiting)
Conditions: breast cancer metastatic, brca 1 gene mutation, brca 2 gene mutation
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, D68.52, J84.83, D68.52, J84.83
Drugs: olaparib, physician's choice chemotherapy
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected
             deleterious.

          -  Histologically or cytologically confirmed breast cancer with evidence of metastatic
             disease.

          -  Prior therapy with an anthracycline and a taxane in either an adjuvant or metastatic
             setting.

          -  Prior platinum allowed as long as no breast cancer progression occurred on treatment
             or if given in adjuvant/neoadjuvant setting at least 12 months from last dose to study
             entry elapsed.

          -  ER/PR breast cancer positive patients must have received and progressed on at least
             one endocrine therapy (adjuvant or metastatic), or have disease that the treating
             physician believes to be inappropriate for endocrine therapy.

          -  ECOG performance status 0-1.

          -  Adequate bone marrow, kidney and liver function.

        Exclusion Criteria:

          -  Prior treatment with PARP inhibitor.

          -  Patients with HER2 positive disease.

          -  More than 2 prior lines of chemotherapy for metastatic breast cancer.

          -  Untreated and/or uncontrolled brain metastases.

          -  Prior malignancy unless curatively treated and disease-free for > 5 years prior to
             study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the
             cervix, DCIS or stage I grade 1 endometrial cancer allowed.

          -  Known HIV (Human Immunodeficiency Virus) infection.

          -  Pregnant or breast-feeding women.